Only about 10 percent of people with a OUD receive any type of specialty treatment. Further, over 40 percent of people with an OUD also have a mental health condition, yet fewer than half (48.0 percent) receive treatment for either disorder.
Many factors contribute to this “treatment gap,” including the inability to access or afford care, fear of shame and discrimination, and lack of screening for substance misuse and substance use disorders in general healthcare settings.
Why Fresh Start Treatment Centers
At Fresh Start we aim to address the factors that contribute to treatment gaps by:
Accepting insurance plans, from both private and government payors, and offering an affordable self-payment plan option for those without insurance.
Conducting business and practicing medicine the same as other specialty clinics where patients are seen for diagnoses such as Diabetes, Asthma or Arthritis.
Consistent with the approach used for other chronic diseases, our treatment plans for OUD will be patient specific and created with input from the patient, the prescriber and other local referral partners and members of the health care team.
Offering the newly FDA-approved Sublocade, the first once-monthly injectable buprenorphine formulation to treat moderate to severe OUD. Sublocade is anticipated to greatly reduce the incidence of the diversion of drugs from their original licit medical purpose. Sublocates’s approval is an important step forward for patients, families and communities battling the opioid epidemic.
All patient services will be provided in a professional physician office setting located at 336 29th Street, Ste. 203 Ashland, KY 41101. Hours of operation will be Monday-Friday from 8am-5pm and our providers will be on-call and available 24-7 via telemedicine services.
Come see us, we are here for you! To make an appointment: